Publications by authors named "Maria A Gonzalez-Rodriguez"
Article Synopsis
- Neurofibromatosis type 2 (NF2) is a rare condition leading to tumors like vestibular schwannomas and meningiomas, and currently lacks FDA approved medication.* -
- Previous research shows that BET inhibition can slow the growth of NF2-related cells, and this study investigates whether combining both BET and FAK inhibition could enhance these effects.* -
- Results indicate that this combination effectively halts the growth of NF2-null cells by disrupting their cell cycle and significantly downregulating FAK1, suggesting a promising new treatment approach for NF2-related tumors.*
Background: Neurofibromatosis type 2 (NF2) is an autosomal dominant genetic disease characterized by development of schwannomas on the VIIIth (vestibular) cranial nerves. Bromodomain and extra-terminal domain (BET) proteins regulate gene transcription and their activity is required in a variety of cancers including malignant peripheral nerve sheath tumors. The use of BET inhibitors as a therapeutic option to treat NF2 schwannomas has not been explored and is the focus of this study.
View Article and Find Full Text PDF